Mapping decrement evoked potentials to guide ablation for ventricular tachycardia in structural heart disease
Tests a new mapping method to guide ablation of ventricular tachycardia in heart disease.
Key facts
- Who runs it
- University Hospitals Coventry and Warwickshire NHS Trust
- Where
- Coventry, United KingdomSee the site
- Trial code
- Registry title
- Optimised Decrement Evoked Potential (DeEP) Mapping to Guide Ventricular Tachycardia (VT) Ablation in Patients With Structural Heart Disease VT
- Status
- Recruiting
- People taking part
- 77 people, planned
- Started
- 11 Apr 2025
- Expected to end
- 3 Dec 2027
- Type of study
- Interventional
- Treatments tested
- Optimised DeEP-guided ablation
- Record updated
- 13 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with structural heart disease and ventricular tachycardia (a dangerous fast heart rhythm) who have an implanted heart device and will have VT ablation as part of standard care.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Ischaemic heart disease with a prior heart attack (MI), or other structural heart disease such as arrhythmogenic cardiomyopathy (ACM), dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), sarcoidosis or myocarditis. People must be able to have VT ablation as part of standard care, urgent or planned.
- Earlier treatment
- People must already have an implanted heart device (CIED), such as a pacemaker, CRT device or ICD. The ablation must use the Abbott mapping catheter and Ensite mapping system.
Main reasons for not taking part
- Severe heart failure (NYHA class IV)
- Life expectancy of less than 12 months
- Ventricular assist device, a moving blood clot inside the heart, or both mechanical aortic and mitral valves
- VT with a reversible cause
- Pregnant or breastfeeding women
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- ≥18 years old
- Patients with cardiac implantable electronic devices (CIED) (e.g. pacemakers, cardiac resynchronisation therapy (CRT) devices, implantable cardioverter defibrillator (ICD) devices)
- Eligible for VT ablation as part of standard care (urgent or elective)
- Ischaemic heart disease and prior myocardial infarction (MI) (using the international definition of MI: Q waves or imaging evidence of regional myocardial akinesis/thinning in the absence of a non-ischemic cause with documentation of prior ischaemic injury) OR other structural heart disease (such as: arrhythmogenic cardiomyopathy (ACM), or dilated cardiomyopathy (DCM), or hypertrophic cardiomyopathy (HCM), or sarcoidosis, or myocarditis)
- Catheter ablation of VT ablation using Abbott intracardiac mapping catheter and Ensite intracardiac mapping system
Who cannot take part
- Enrolment in a concurrent interventional clinical study that in the judgement of the investigator would increase risk to the patient or deem the patient inappropriate to participate in this study
- New York Heart Association (NYHA) class IV heart failure
- Lacks capacity to provide informed consent
- Life expectancy of less than 12 months
- Implanted with a ventricular assist device
- Presence of mobile intracardiac thrombus
- Reversible cause of VT
- Women who are pregnant or nursing
- Both mechanical aortic and mitral valves
Where in United Kingdom
- University Hospitals Coventry & Warwickshire NHS TrustCoventry, United KingdomContact: Shivam JoshiTaking people
About the trial
What the trial wants to find out
Ventricular tachycardia (VT) is a life-threatening heart rhythm disorder. Special pacemakers called implantable cardiac defibrillators (ICDs) help treat VT episodes, however they do not prevent the VT episodes from occurring. Catheter ablation for VT is a minimally-invasive and established procedure for preventing VT recurrence. This involves placing wires in the heart to find the diseased areas that are responsible for the VT episodes. The diseased areas are shown on computer-generated maps and are later removed via controlled tissue heating (ablation). A major challenge during the VT ablation procedure is locating the diseased area responsible for the VT episodes. Several methods have been described to locate the diseased heart area, however these methods are not always effective.
Read full original descriptionShow less
In this study, we aim to improve the identification of the diseased heart areas responsible for the VT episodes using a novel method. Our research group have developed, tested and peer-reviewed this improved method of locating diseased areas by looking for signals called decrementing evoked potentials (DeEPs). Ablation will target DeEPs shown on the computer-generated maps. We will assess if VT can be triggered at the end of the procedure. Patients will be monitored over 12 months to see if ablation of DeEPs leads to a reduction in VT episodes. We aim to recruit 77 patients with established heart disease of any cause, who have suffered VT episodes with ICDs. Suitable patients will be identified and recruited from inpatient and outpatient settings. A quality-of-life questionnaire will be completed by patients before and after the ablation procedure. The procedure will be performed as routine standard of care, in the cardiac catheter laboratory across multiple recruiting cardiac centres in the UK providing well established VT ablation service.
Overall, this study will contribute towards developing refined VT ablation techniques, aiming to improve patient outcomes.
The group in the trial
- Optimised DeEP-guided ablationTreatment being tested
DeEP mapping in VT ablation.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Optimised Decrement Evoked Potential (DeEP) Mapping to Guide Ventricular Tachycardia (VT) Ablation in Patients With Structural Heart Disease VT
- Plain-language title
- Mapping decrement evoked potentials to guide ablation for ventricular tachycardia in structural heart diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 13 April 2026